Skip to main content
. 2021 Jan 1;11(4):1609–1625. doi: 10.7150/thno.48153

Figure 7.

Figure 7

Endothelial Foxp1 deletion attenuates the simvastatin-mediated improvement of the cardiac dysfunction. A-D, Endothelial Foxp1 deletion mice exhibits reduction of the simvastatin improvement of the cardiac systolic dysfunction shown by LVEF (A) and LVFS (B), and the diastolic function shown by E/e' ratio (C) and E/A ratio (D) compared with the vehicle control (n=8). E-F, Endothelial Foxp1 deletion mice exhibits decrease of the TAC-induced elevated heart to body weight ratio (E), LV mass (F) compared with the vehicle control (n=8). G, The working model of the novel mechanism of simvastatin's prevention of TAC-induced cardiac remodeling through EC-KLF2 repression of EC-TGFβ1 or through EC-Klf2-Foxp1 transcription factor network, and therefore improves the progression of cardiac dysfunction to HF. Data are means ± S.E.M. *P<0.05, **P<0.01 and n.s. not significant. 2-way ANOVA with Turkey test (A-F).